What happened
Edison Scientific will deploy its AI platform and Kosmos, its AI scientist, across Pfizer's biopharmaceutical R&D pipeline, including oncology, internal medicine and immunology, with Kosmos accessing Pfizer's data.
Why it matters
Kosmos learns continuously from both public and Pfizer's proprietary data, which Edison says will give the pharma giant advantages in compounding and proprietary intelligence for drug discovery.
WHO IT HITSPfizer's R&D scientists in oncology, internal medicine, and immunology stand to gain AI support for critical decisions, while Edison's forward-deployed engineers embed Kosmos into those workflows.
Summaries like this, every morning.
The Pfizer collaboration follows Edison's earlier deal with Incyte in 2026, when Kosmos was deployed to help generate predictive models of therapeutic performance. That sequence suggests Edison is building a repeatable model for embedding its AI scientist inside large pharma R&D organizations, rather than selling a standalone tool.
A central piece of the arrangement is how Kosmos draws on two distinct data channels: publicly available data and Pfizer's proprietary internal drug development data. According to Edison CEO Sam Rodriques, Pfizer's decades of data on what works and what doesn't serve as the foundation for Kosmos, with lessons from each program intended to inform others. The company says every experiment and clinical readout strengthens the entire system.
Edison's forward-deployed scientists and engineers are meant to shape how Kosmos fits into Pfizer's specific workflows, helping determine how research gets organized and decisions get made. Edison spun out of the nonprofit research lab FutureHouse in 2025, backed by $70 million in funding.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
Anthropic's public filing showed little on forthcoming revenues after sales decelerated from the second to the…
Tesla rose 7.4% this week, according to MarketSurge, standing out as other Magnificent Seven AI stocks sold of…
At AHCJ's fall summit, Amgen's David Reese said executives promising AI will cure 'all disease' typically have…
JAC Recruitment's survey of 1,010 managers aged 30–50 found 80.2% say AI skills affect their market value, whi…
TDK grew revenue 38.3% year on year to ¥741.0 billion for the quarter, Murata Manufacturing rose 20.7% to ¥502…
The S&P 500 closed at 7,580.07 versus 7,623.68 a week earlier, and the Nasdaq fell to about 25,436.99, as Alph…
